Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
NCT ID: NCT00592774
Last Updated: 2013-02-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
146 participants
INTERVENTIONAL
2008-01-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
NCT00592904
RN624 For Pain Of Post-Herpetic Neuralgia
NCT00568321
Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia
NCT01058642
The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain
NCT00376454
A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety
NCT02065349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Cohort 1
Placebo
2 mg titrated up to 8 mg maximum; taken once daily.
Perampanel Cohort 1, 3-week Titration
E2007 (perampanel)
2 mg titrated up to 8 mg maximum; taken once daily.
Placebo Cohort 2
Placebo
2 mg titrated up to 8 mg maximum; taken once daily.
Perampanel Cohort 2, 1-week Titration
E2007 (perampanel)
2 mg titrated up to 8 mg maximum; taken once daily.
Perampanel Cohort 2, 2- Week Titration
E2007 (perampanel)
2 mg titrated up to 8 mg maximum; taken once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E2007 (perampanel)
2 mg titrated up to 8 mg maximum; taken once daily.
Placebo
2 mg titrated up to 8 mg maximum; taken once daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provide written informed consent, prior to entering the study or undergoing any study procedures.
2. Male and female patients ≥18 years of age. Females should be either of nonchildbearing potential as a result of surgery or menopause (1 year after onset), or of childbearing potential and practicing a medically acceptable method of contraception. Acceptable contraception includes: abstinence, a barrier method plus spermicide, or intrauterine device \[IUD\]. Those females using hormonal contraceptives must also be using an additional approved method of contraception (e.g., a barrier method plus spermicide or IUD). Contraceptive use must start at least 1 month before Visit 1, be practiced throughout the entire study period, and continue for 1 month after the end of the study. They must also have a negative serum beta-human chorionic gonadotropin (β-hCG) at Visit 1, and a negative urine pregnancy test at Baseline Visit 2.
3. PHN of at least 6 months duration; the onset of PHN is defined as the time from healing of herpes zoster skin lesions.
4. Pain over the past 6 months, and not in a clinically identifiable improving or worsening trend, based on medical history.
5. Score of ≥ 40 mm on the visual analog scale (VAS) of the short form McGill Pain Questionnaire (SF-MPQ) at both Visit 1 and Baseline (Visit 2 prior to randomization).
6. Have completed the patient diary for at least 6 of the 7 days prior to Visit 2 (Baseline).
7. Average daily pain score of ≥ 4, on 11-point Likert scale during the 7 days prior to randomization \[from the diaries\].
8. Reliable and willing and able to cooperate with all study procedures, including the following examples:
* Accurately entering the diary on a daily basis
* Returning for study visits on the required dates
* Accurately and reliably reporting symptoms (including treatment-emergent signs and symptoms)
* Taking study drug as required by protocol
9. Be on stable analgesic treatment (same medication(s)) or stable nonpharmacological pain treatment for at least 4 weeks prior to Visit 1 and remain on this stable treatment throughout the study. Nonpharmacologic pain treatment includes the following:
* relaxation/hypnosis
* physical or occupational therapy
* mental-health counseling
* acupuncture
* injections
* blocks, etc.
* Episodic or periodic pharmacologic treatments such as monthly injections for treatment of pain (eg, local anesthetics) will not be permitted.
* Up to 4 g of acetaminophen/day is permitted as rescue medication, as needed, during the trial.
Exclusion Criteria
1. Any condition that could interfere with the conduct of the trial or confound efficacy evaluations including the following examples: pain or neuropathy from another cause (including painful diabetic neuropathy), such as central pain, radiculopathy, painful arthritis, etc.
2. Motivation by secondary gain, or where there is a negative-incentive to achieving pain and functional relief (eg, litigation). This will be determined from the medical history and is at the discretion of the investigator.
3. Inability to cooperate with protocol, for any reason.
4. Clinically significant, progressive, or potentially unstable disease of any body system including cardiovascular, gastrointestinal, CNS, psychiatric, endocrine, or immunologic, including patients with any of the following broad disease categories:
1. Systemic infections (eg, human immunodeficiency virus \[HIV\], hepatitis, tuberculosis \[TB\], syphilis); lack of appropriate medical history of these conditions is acceptable,
2. History of past (within the past 12 months) or present drug or alcohol abuse as per the Diagnostic and Statistical Manual - 4th Edition (DSM IV) criteria,
3. History of acute coronary syndrome within the past 12 months,
4. Active cancer within the previous 5 years (the exception is fully treated, non-melanoma skin cancer such as basal cell carcinoma),
5. Systemic chemotherapy or immunotherapy within the past 5 years,
6. History of major depression, bipolar disease, psychosis or suicidal ideation or attempts within the past 5 years,
7. History of major systemic allergy such as anaphylactoid reactions or Stevens-Johnson syndrome (however, patients with limited allergies such as contact dermatitis or minor allergy to penicillin are acceptable).
5. Any of the following laboratory abnormalities at Visit 1:
1. Clinically significant ECG abnormality, including prolonged QTc (defined as QTcB \> 450 msec),
2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times the upper limit of normal (ULN),
3. Clinically significant abnormal white blood cell (WBC), absolute neutrophil, or platelet count values,
4. Any other clinically significant laboratory value.
6. Exposure to an investigational drug within the 30 days prior to Visit 1 or exposure ever to perampanel.
7. Females who are pregnant, lactating, or planning to become pregnant during the study.
8. Use of any medication known to be a strong inducer of CYP3A4 activity within 4 weeks prior to Visit 1; use of CYP3A4 inducers is prohibited for the entire study duration.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allison Mann, MD
Role: STUDY_DIRECTOR
Eisai Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peoria, Arizona, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Milford, Connecticut, United States
Boca Raton, Florida, United States
Bradenton, Florida, United States
Daytona Beach, Florida, United States
Delray Beach, Florida, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Kissimmee, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Orlando, Florida, United States
Palm Beach Gardens, Florida, United States
Sarasota, Florida, United States
St. Petersburg, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
Pain and Rehabilitation Clinic of Chicago
Chicago, Illinois, United States
Chicago, Illinois, United States
Towson, Maryland, United States
Boston, Massachusetts, United States
West Yarmouth, Massachusetts, United States
Southfield, Michigan, United States
Missoula, Montana, United States
Las Vegas, Nevada, United States
Brooklyn, New York, United States
High Point, North Carolina, United States
Winston-Salem, North Carolina, United States
Kettering, Ohio, United States
Bensalem, Pennsylvania, United States
Norristown, Pennsylvania, United States
Warwick, Rhode Island, United States
Dallas, Texas, United States
Kelowna, British Columbia, Canada
Sarnia, Ontario, Canada
Toronto, Ontario, Canada
Pointe-Claire, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E2007-A001-218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.